Soin Therapeutics is a pharmaceutical company that is developing new medications to treat rare, orphan diseases. Our lead product is a novel formulation of naltrexone for patients who suffer from complex regional pain syndrome (CRPS). It has received orphan drug status from the FDA. CRPS is a painful, debilitating disease and we believe we found a solution that can be helpful to many people who are suffering.
Complex Regional Pain Syndrome is a rare, orphan disease characterized by severe pain, usually starting in an extremity, and associated with extreme swelling, limited range of motion, changes to the skin or bone structure, and debilitating pain
At Soin Therapeutics our ultimate goal is to get a high quality and effective formulation of low dose naltrexone on the market. We have developed a new oral pill that we believe has several advantages to help suffering patients. Our current formulation still requires FDA approval.
Published in a major medical journal, this review article written by the Soin Team highlights the clinical data on the use of LDN to treat CRPS.
Published in the journal Pain Medicine Case Reports, this article written by the Soin Team is a case report of the use of LDN to treat CRPS.
Soin Therapeutics was granted an Orphan Drug Designation by the FDA to treat CRPS with LDN
Dr. Amol Soin is a quadruple board certified pain management physician who saw the suffering of patients with CRPS and decided to do something about it. Dr. Soin has invented multiple medications and medical devices to treat pain without addiction. He has founded numerous biotech companies, holds several patents, his research has been published extensively in multiple medical journals, and has served as president of the Ohio Medical Board, president of the American Society of Interventional Pain Physicians, president of the Society of Interventional Pain Management Surgery Centers, as well as several other organizations. He is also a professor at three different medical schools, and runs his own pain management research laboratory. Additionally, Dr. Soin has 5 college degrees including two from Ivy League Schools: Dartmouth and Brown.
Low Dose Naltrexone, LDN, is a medication that is used to treat addiction. However, recent evidence suggests that at low doses (5mg or less) it has very unique effects at treating pain and the disease cascade associated with complex regional pain syndrome (CRPS).
LDN acts on a receptor in the body known as TLR (Toll Like receptor) and through this, has been shown to reduce pain. Additionally, it is thought to increase your body's endorphins, which are natural pain killers. It is also thought to decrease the activity of cells called microglial cells which are responsible for pain, as well as decrease the activity of interleukins which are involved in nerve inflammation. The drug seems uniquely suited to treat the disease process in CRPS.
Soin Therapeutics Completes Formulation Work on Novel Pill to Treat CRPS
Soin Therapeutics was featured in an article on the use of LDN to treat CRPS
Soin Therapeutics obtained Orphan Drug Status from the FDA on their lead LDN drug
Amol Soin was featured on a podcast for Entrepreneur Magazine discussing LDN
Currently LDN for CRPS is NOT FDA approved. We plan to complete rigorous human trials to prove safety and efficacy for our novel formulation. Then we can finally help patients who are suffering from CRPS. We look forward to advancing the science and for a brighter tomorrow for our patients.
Mon | 09:00 am – 05:00 pm | |
Tue | 09:00 am – 05:00 pm | |
Wed | 09:00 am – 05:00 pm | |
Thu | 09:00 am – 05:00 pm | |
Fri | 09:00 am – 05:00 pm | |
Sat | Closed | |
Sun | Closed |
Copyright © 2022 Soin Therapeutics - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.